GlassScriptPhysician profile
Ramsey Joseph Daher
NPI 1710206115
$7,332.29
in general payments reported to CMS, 2019-2025
33 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $352 · 2021: $61.33 · 2022: $812 · 2023: $1,082 · 2024: $2,270 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,335.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,067.72 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $808.36 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $748.03 | 2019-2025 | Xifaxan |
| Pfizer INC. | $633.86 | 2019-2025 | |
| Celgene Corporation | $574.23 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $430.71 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $408.91 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.09 | 2019-2024 | Gattex, Entyvio |
| Qol Medical, LLC | $248.36 | 2024-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $223.79 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $218.70 | 2024-2025 | General - Endochoice, Speedband Superview Super 7 |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $181.62 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $180.13 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $146.30 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $142.05 | 2019-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $99.81 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $98.22 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $89.78 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $87.37 | 2025 | Iqirvo |
| Lilly USA, LLC | $81.81 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $64.54 | 2024 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $52.51 | 2023-2024 | Ocaliva |
| Stryker Corporation | $42.41 | 2024 | Neptune |
| Nestle Healthcare Nutrition INC. | $41.87 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.80 | 2024 | Cyltezo |
| Madrigal Pharmaceuticals | $34.75 | 2024 | Resmetirom |
| Evoke Pharma, INC. | $33.13 | 2025 | |
| Allergan, INC. | $24.60 | 2019 | |
| Celltrion USA INC. | $22.49 | 2024 | Zymfentra |
| Novo Nordisk INC | $20.04 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $19.13 | 2019 | |
| Orphalan INC | $16.50 | 2024 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsey Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.